Literature DB >> 20736478

Acyclovir exposure and birth defects: an important advance, but more are needed.

James L Mills, Tonia C Carter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20736478      PMCID： PMC4158607          DOI： 10.1001/jama.2010.1214

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.

Authors:  R Reiff-Eldridge; C R Heffner; S A Ephross; P S Tennis; A D White; E B Andrews
Journal:  Am J Obstet Gynecol       Date:  2000-01       Impact factor: 8.661

3.  Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States.

Authors:  Fujie Xu; Lauri E Markowitz; Sami L Gottlieb; Stuart M Berman
Journal:  Am J Obstet Gynecol       Date:  2007-01       Impact factor: 8.661

4.  Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.

Authors:  Björn Pasternak; Anders Hviid
Journal:  JAMA       Date:  2010-08-25       Impact factor: 56.272

5.  The acquisition of herpes simplex virus during pregnancy.

Authors:  Z A Brown; S Selke; J Zeh; J Kopelman; A Maslow; R L Ashley; D H Watts; S Berry; M Herd; L Corey
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245

6.  Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study.

Authors:  Chaveewan Ratanajamit; Mette Vinther Skriver; Peter Jepsen; Virasakdi Chongsuvivatwong; Jørn Olsen; Henrik Toft Sørensen
Journal:  Scand J Infect Dis       Date:  2003

7.  Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999.

Authors:  Katherine M Stone; Robbin Reiff-Eldridge; Alice D White; José F Cordero; Zane Brown; E Russell Alexander; Elizabeth B Andrews
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2004-04

8.  The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England.

Authors:  L V Wilton; G L Pearce; R M Martin; F J Mackay; R D Mann
Journal:  Br J Obstet Gynaecol       Date:  1998-08
  8 in total
  3 in total

Review 1.  Human teratogens update 2011: can we ensure safety during pregnancy?

Authors:  Sonja A Rasmussen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-02-13

2.  The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007.

Authors:  Lyndsay A Avalos; Hong Chen; Chunmei Yang; Susan E Andrade; William O Cooper; Craig T Cheetham; Robert L Davis; Sascha Dublin; Tarek A Hammad; Sigal Kaplan; Pamala A Pawloski; Marsha A Raebel; Pamela E Scott; David H Smith; Sengwee Toh; De-Kun Li
Journal:  Matern Child Health J       Date:  2014-01

Review 3.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.